674 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
TG Therapeutics Up on FDA Consent for Leukemia Study http://www.zacks.com/stock/news/190649/tg-therapeutics-up-on-fda-consent-for-leukemia-study?cid=CS-ZC-FT-190649 Sep 18, 2015 - TG Therapeutics (TGTX) reached an agreement with the FDA related to a Special Protocol Assessment of a phase III study design for TG-1101 for chronic lymphocytic leukemia.
3M Invests for Minority Stake in StrongArm Technologies http://www.zacks.com/stock/news/190601/3m-invests-for-minority-stake-in-strongarm-technologies?cid=CS-ZC-FT-190601 Sep 18, 2015 - 3M Safety and Graphics Business Group, a part of 3M Company (MMM), recently announced a minority equity investment in StrongArm Technologies Inc., - a company that designs innovative safety products.
Eli Lilly (LLY) in Focus: Stock Jumps 6.6% in Session http://www.zacks.com/stock/news/190556/eli-lilly-lly-rises-66?cid=CS-ZC-FT-190556 Sep 18, 2015 - Eli Lilly and Company (LLY) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
GW Pharmaceuticals Up on Encouraging Schizophrenia Data http://www.zacks.com/stock/news/190320/gw-pharmaceuticals-up-on-encouraging-schizophrenia-data?cid=CS-ZC-FT-190320 Sep 16, 2015 - GW Pharmaceuticals plc (GWPH) announced encouraging top-line data from an exploratory phase IIa study on cannabidiol in patients suffering from schizophrenia who had previously failed to respond adequately to first-line anti-psychotic medications.
Amgen, Novartis Team Up; Bone Drug Positive in Phase III http://www.zacks.com/stock/news/188757/amgen-novartis-team-up-bone-drug-positive-in-phase-iii?cid=CS-ZC-FT-188757 Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
Bristol-Myers Inks Another Immuno-Oncology Drug Deal http://www.zacks.com/stock/news/188393/bristol-myers-inks-another-immuno-oncology-drug-deal?cid=CS-ZC-FT-188393 Aug 31, 2015 - Bristol-Myers Squibb Company (BMY) announced that it has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute.
Why Eli Lilly (LLY) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/188271/eli-lilly-is-in-a-good-position-to-beat-earnings-at-its-next-report?cid=CS-ZC-FT-188271 Aug 31, 2015 - Eli Lilly has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat
Eli Lilly's (LLY) Diabetes Drug Synjardy Gets U.S. Approval http://www.zacks.com/stock/news/188169/eli-lillys-lly-diabetes-drug-synjardy-gets-us-approval?cid=CS-ZC-FT-188169 Aug 28, 2015 - Eli Lilly (LLY) announced that the FDA has approved its diabetes drug, Synjardy, for the treatment of patients with type II diabetes.
Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled http://www.zacks.com/stock/news/188033/oncolytics-reolysin-phase-ii-lung-cancer-study-enrolled?cid=CS-ZC-FT-188033 Aug 27, 2015 - Oncolytics Biotech (ONCY) completed enrolling patients in a phase II study on Reolysin for the treatment of non-small cell lung cancer.
Novo Nordisk to Start PIONEER Program on Semaglutide http://www.zacks.com/stock/news/188031/novo-nordisk-to-start-pioneer-program-on-semaglutide?cid=CS-ZC-FT-188031 Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.

Pages: 1...62636465666768

<<<Page 67